Hangzhou Tigermed Consulting Co Ltd (Tigermed) is a contract research organization (CRO) for the biopharmaceutical and medical device industry. The company’s preclinical service portfolio includes medicinal chemistry, compound screening, drug metabolism and pharmacokinetics (DMPK), safety and toxicology, bioanalytical, and formulation research and development (CMC). Tigermed offers medical writing expertise in various treatment areas and types of document comprising investigational new drug (IND) application, clinical trial, and post-marketing writing. The company provides protocol design and medical writing services in oncology, haematology, orthopaedics, cardiovascular disease, respiratory, infectious disease, and vaccine. Tigermed’s solutions that help meet full regulatory compliance include Phase I-IV drug and medical device protocols, clinical study reports (Phase I-IV) comprising patient narratives, appendices, publishing, basic results’ disclosure, lay summaries, and redaction, informed consent forms, clinical development plan, investigator brochures, and clinical overview, clinical summaries, integrated summaries of safety and efficacy, and risk management plan (RMP). The company’s post-marketing clinical research solutions are based on medical, regulatory, clinical, and real-world evidence (RWE) research to provide the latest strategies and research, providing post-marketing strategies for new drugs, post-marketing safety monitoring of new drugs, and development and review of real-world studies to facilitate the drug development plan.
You have successfully subscribed and will receive the next available issues